Leerink Partners Cuts Price Target on Aegerion Pharma (AEGR) Following 1Q Miss and Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Aegerion Pharmaceuticals Announces First Quarter 2016 Financial Results
May 16, 2016 4:05 PM EDTCompany records $35.7 million in total net product sales    Company now expects full-year revenues for JUXTAPID to be between $90 million and $100 millionCompany continues to expect full-year revenues for MYALEPT to be between $40 million and $50 million
CAMBRIDGE, Mass., May 16, 2016 (GLOBE NEWSWIRE) -- Â Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its financial results and business... More
